@paulg And thus the challenge of Sovaldi—they get hammered for developing and pricing a cure versus a perpetual treatment.
Markets are usually quite clever but one place they break is in encouraging treatments rather than vaccines. Subscription revenue.
-
-
Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@paulg do you think this would be different if the barriers to entry for medicine were lower? -
@jbackus3 pretty sure he's using that as an analogy - Show replies
New conversation -
-
-
This Tweet is unavailable.
-
@romansnitko@paulg before FDA regulation there were also some terrible side effects
End of conversation
-
-
-
@paulg Unfortunately more than just a metaphor, since big pharma might be the biggest offenders.Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@SamGichuru Would that be 'pay every other time' rather than a one off? ....@paulgThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@paulg also in the medical realm, encouraging longevity rather than quality of lifeThanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@paulg On the buy side, also why health ins. is a mess: "Profit" and "Health" not necessarily aligned. If cheaper to deny a claim...well...Thanks. Twitter will use this to make your timeline better. UndoUndo
-
-
-
@paulg Though if you're a biotech startup with nothing to lose, finding a successful vaccine is pretty sweet too...Thanks. Twitter will use this to make your timeline better. UndoUndo
-
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.